BIO-CAT Inc. has announced that the U.S. Patent and Trademark Office has granted the company a patent for the use of a lipase enzyme to digest dietary fats, resulting in the reduction in levels of triglycerides in the blood stream. BIO-CAT, a Virginia-based biotech company specializing in enzyme applications, received U.S. patent number US 8,268,305 entitled “Methods and Compositions to Reduce Serum Levels of Triacylglycerides in Human Beings Using a Fungal Lipase.” The written patent on this application was issued Sept. 18, 2012.
“High triglycerides are a major problem for many people and we knew the lipase enzyme had the ability to break the fats down,” said Ed Schuler, BIO-CAT CEO. “Our innovation is demonstrating the complete breakdown of fats during digestion in the stomach. This led to further observations where blood triglycerides were substantially reduced in initial test cases.”
The innovation to use lipase to reduce triglycerides stemmed from previous work completed by BIO-CAT that resulted in a 2011 patent (US 8,071,089 “A Composition With a Fungal (Yeast) Lipase and Method For Treating Malabsorption in Cystic Fibrosis As Well As People Suffering From Pancreatic Lipase Insufficiency”) using an enzyme mixture including lipase to aid in the digestion of fats and other materials in the diet. This discovery is targeted to help people, especially those affected by pancreatic insufficiency, cystic fibrosis, and other similar ailments, obtain more nutrition from their food. BIO-CAT will be conducting further clinical studies to optimize both technologies in order to bring the product to market.